Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXAI Exscientia	$4.84	$4.97	$3.80 ▼ $6.49	$632.93M	0.83	685,753 shs	N/A
GOOG Alphabet	$176.91 -0.3%	$168.37	$142.66 ▼ $208.70	$2.15T	1.01	21.13 million shs	24.84 million shs
NVDA NVIDIA	$153.30 -3.0%	$132.18	$86.62 ▼ $158.71	$3.85T	2.13	268.61 million shs	212.55 million shs
RXRX Recursion Pharmaceuticals	$5.13 +1.4%	$4.87	$3.79 ▼ $12.36	$2.06B	0.91	15.84 million shs	37.96 million shs
SAN Banco Santander	$8.26 -0.5%	$7.75	$4.27 ▼ $8.39	$125.77B	0.99	4.10 million shs	6.28 million shs
SDGR Schrodinger	$20.61 +2.4%	$22.96	$16.60 ▼ $28.47	$1.48B	1.58	914,073 shs	902,735 shs
SNY Sanofi	$49.05 +1.5%	$50.84	$45.80 ▼ $60.12	$118.48B	0.49	2.34 million shs	1.60 million shs
SNYNF Sanofi	$96.54 +1.6%	$101.87	$91.81 ▼ $122.03	N/A	N/A	21,678 shs	3,078 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXAI Exscientia	0.00%	0.00%	0.00%	0.00%	-5.10%
GOOG Alphabet	-0.49%	+6.86%	+3.82%	+11.65%	-3.29%
NVDA NVIDIA	+0.15%	+9.59%	+17.66%	+43.43%	+27.89%
RXRX Recursion Pharmaceuticals	+0.60%	+4.76%	+20.48%	-0.59%	-32.53%
SAN Banco Santander	+0.55%	+3.62%	+4.02%	+22.36%	+79.05%
SDGR Schrodinger	-2.38%	-1.13%	-6.98%	+6.79%	+4.03%
SNY Sanofi	+0.96%	+0.27%	-2.21%	-11.10%	-0.43%
SNYNF Sanofi	-2.46%	+0.17%	-4.98%	-13.90%	-0.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EXAI Exscientia	0.2415 of 5 stars	1.0	0.0	0.0	0.0	0.6	1.7	0.6
GOOG Alphabet	4.857 of 5 stars	3.4	3.0	1.7	2.9	2.8	1.7	3.1
NVDA NVIDIA	4.8881 of 5 stars	3.5	5.0	1.7	3.0	2.7	2.5	1.9
RXRX Recursion Pharmaceuticals	1.867 of 5 stars	3.2	1.0	0.0	0.0	2.5	1.7	0.6
SAN Banco Santander	4.1265 of 5 stars	0.0	5.0	2.5	2.8	2.0	0.0	3.8
SDGR Schrodinger	2.6082 of 5 stars	3.5	2.0	0.0	0.0	2.1	2.5	0.6
SNY Sanofi	4.2571 of 5 stars	3.6	4.0	2.5	0.0	2.0	0.0	3.1
SNYNF Sanofi	0.9166 of 5 stars	0.0	2.0	1.7	4.0	1.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXAI Exscientia	2.00	Hold	$5.00	3.31% Upside
GOOG Alphabet	2.82	Moderate Buy	$206.38	16.66% Upside
NVDA NVIDIA	2.93	Moderate Buy	$175.78	14.66% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	36.45% Upside
SAN Banco Santander	3.00	Buy	N/A	N/A
SDGR Schrodinger	3.00	Buy	$32.80	59.15% Upside
SNY Sanofi	3.13	Buy	$61.50	25.38% Upside
SNYNF Sanofi	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	GOOG Alphabet	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/26/2025	GOOG Alphabet	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/25/2025	NVDA NVIDIA	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$175.00 ➝ $250.00
6/17/2025	NVDA NVIDIA	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$170.00 ➝ $200.00
6/16/2025	NVDA NVIDIA	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$175.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/4/2025	SAN Banco Santander	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/3/2025	SNY Sanofi	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	GOOG Alphabet	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$220.00
6/2/2025	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$56.00
5/29/2025	NVDA NVIDIA	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXAI Exscientia	$25.60M	24.72	N/A	N/A	$2.54 per share	1.91
GOOG Alphabet	$350.02B	6.13	$9.45 per share	18.73	$26.67 per share	6.63
NVDA NVIDIA	$130.50B	28.66	$2.97 per share	51.67	$3.44 per share	44.56
RXRX Recursion Pharmaceuticals	$58.84M	35.44	N/A	N/A	$2.61 per share	1.97
SAN Banco Santander	$66.96B	1.87	$1.08 per share	7.65	$7.34 per share	1.13
SDGR Schrodinger	$207.54M	7.29	N/A	N/A	$5.78 per share	3.57
SNY Sanofi	$44.46B	2.71	$5.41 per share	9.06	$33.20 per share	1.48
SNYNF Sanofi	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXAI Exscientia	-$181.56M	-$1.51	N/A	N/A	N/A	-882.09%	-49.10%	-33.13%	N/A
GOOG Alphabet	$100.12B	$8.97	19.72	17.29	1.25	30.86%	34.54%	25.07%	7/22/2025 (Estimated)
NVDA NVIDIA	$72.88B	$3.10	49.45	38.52	1.40	51.69%	105.09%	72.19%	8/27/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)
SAN Banco Santander	$13.61B	$0.87	9.49	8.98	0.90	16.92%	12.26%	0.72%	7/23/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
SNY Sanofi	$6.02B	$2.80	17.52	10.33	0.99	14.56%	17.15%	9.80%	7/24/2025 (Estimated)
SNYNF Sanofi	N/A	$3.08	31.30	∞	N/A	N/A	N/A	N/A	7/31/2025 (Estimated)

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	SNY Sanofi	$0.98	N/A	N/A	N/A	N/A	N/A
7/23/2025	Q2 2025	SAN Banco Santander	$0.27	N/A	N/A	N/A	N/A	N/A
7/22/2025	Q2 2025	GOOG Alphabet	$2.12	N/A	N/A	N/A	$93.67 billion	N/A
5/28/2025	Q1 2026	NVDA NVIDIA	$0.87	$0.81	-$0.06	$0.76	$43.09 billion	$44.06 billion
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
4/30/2025	Q1 2025	SAN Banco Santander	$0.22	$0.22	N/A	$0.22	$15.94 billion	$17.69 billion
4/24/2025	Q1 2025	GOOG Alphabet	$2.02	$2.81	+$0.79	$2.81	$89.30 billion	$90.23 billion
4/24/2025	Q1 2025	SNY Sanofi	$0.90	$0.94	+$0.04	$0.80	$9.79 billion	$10.41 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A
GOOG Alphabet	$0.84	0.47%	N/A	9.36%	1 Years
NVDA NVIDIA	$0.04	0.03%	N/A	1.29%	1 Years
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SAN Banco Santander	$0.18	2.18%	N/A	20.69%	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.60	3.26%	N/A	57.14%	N/A
SNYNF Sanofi	$2.80	2.90%	N/A	90.78%	N/A

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/28/2025	NVDA NVIDIA	quarterly	$0.01	0.03%	6/11/2025	6/11/2025	7/3/2025
4/23/2025	GOOG Alphabet	quarterly	$0.21	0.5%	6/9/2025	6/9/2025	6/16/2025
4/15/2025	SNY Sanofi	annual	$2.0369	3.1%	5/9/2025	5/9/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXAI Exscientia	0.06	4.54	4.54
GOOG Alphabet	0.03	1.77	1.77
NVDA NVIDIA	0.10	3.39	2.96
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11
SAN Banco Santander	N/A	0.25	0.25
SDGR Schrodinger	N/A	3.45	3.45
SNY Sanofi	0.16	1.37	0.69
SNYNF Sanofi	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXAI Exscientia	41.58%
GOOG Alphabet	27.26%
NVDA NVIDIA	65.27%
RXRX Recursion Pharmaceuticals	89.06%
SAN Banco Santander	9.19%
SDGR Schrodinger	79.05%
SNY Sanofi	14.04%
SNYNF Sanofi	30.06%

Insider Ownership

Company	Insider Ownership
EXAI Exscientia	16.40%
GOOG Alphabet	12.99%
NVDA NVIDIA	4.17%
RXRX Recursion Pharmaceuticals	8.43%
SAN Banco Santander	9.48%
SDGR Schrodinger	8.60%
SNY Sanofi	1.00%
SNYNF Sanofi	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXAI Exscientia	280	130.77 million	109.32 million	Optionable
GOOG Alphabet	190,200	12.14 billion	10.56 billion	Optionable
NVDA NVIDIA	36,000	24.40 billion	23.38 billion	Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable
SAN Banco Santander	199,958	15.15 billion	13.72 billion	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
SNY Sanofi	82,878	2.45 billion	2.43 billion	Optionable
SNYNF Sanofi	91,600	N/A	N/A	Not Optionable

SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Headlines

Recent News About These Companies

Sanofi (ENXTPA:SAN) Gains Orphan Drug Status In Japan For CIDP Treatment

June 30 at 3:48 PM | finance.yahoo.com

Kymera’s partnerships with Sanofi and Gilead drive value

June 27, 2025 | finance.yahoo.com

Sanofi (SAN.PA)

June 20, 2025 | sg.finance.yahoo.com

Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade

June 18, 2025 | seekingalpha.com

Sanofi : Dupixent Shows Superior Results To Xolair In Phase 4 Study For Sinus And Asthma Treatment

June 17, 2025 | nasdaq.com

Sanofi (SNYNF) Gets a Buy from Berenberg Bank

June 14, 2025 | theglobeandmail.com

Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand

June 11, 2025 | finance.yahoo.com

Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

June 9, 2025 | finance.yahoo.com

Sanofi Speeds Up Global Beyfortus Shipments Ahead Of 2025-2026 RSV Season

June 9, 2025 | kalkinemedia.comK

Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)

June 4, 2025 | theglobeandmail.com

Sanofi (SNYNF) Gets a Hold from Deutsche Bank

June 4, 2025 | theglobeandmail.com

M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal

June 3, 2025 | uk.finance.yahoo.com

Sanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD Trial

June 1, 2025 | uk.finance.yahoo.com

J.P. Morgan Keeps Their Hold Rating on Sanofi (SNYNF)

June 1, 2025 | theglobeandmail.com

Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management

May 20, 2025 | finance.yahoo.com

Bristol-Myers, Sanofi ink $700M settlement with Hawaii to resolve Plavix lawsuit

May 10, 2025 | msn.com

Sanofi to be No.1 in consumer health via Boehringer multi-billion swap

April 26, 2025 | pharmaphorum.comP

Goldman Sachs Reaffirms Their Hold Rating on Sanofi (SNYNF)

April 25, 2025 | markets.businessinsider.com

Sanofi proposes annual dividend of €3.92, a hike of 4.26% from prior dividend

April 24, 2025 | seekingalpha.com

Barclays Keeps Their Buy Rating on Sanofi (SNYNF)

April 24, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
By Thomas Hughes | June 26, 2025
View NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
Alphabet Enters a Bull Market: Is It Time to Buy?
By Ryan Hasson | June 14, 2025
View Alphabet Enters a Bull Market: Is It Time to Buy?
Why Nebius Group Is One of the Top AI Stocks to Watch
By Thomas Hughes | June 17, 2025
View Why Nebius Group Is One of the Top AI Stocks to Watch
Alphabet’s Comeback: The Hidden Engines Powering Google
By Ryan Hasson | June 23, 2025
View Alphabet’s Comeback: The Hidden Engines Powering Google
Alphabet Stock Analysis: What's Next—Bull or Bear Market?
By Ryan Hasson | June 5, 2025
View Alphabet Stock Analysis: What's Next—Bull or Bear Market?

SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Company Descriptions

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Alphabet NASDAQ:GOOG

$176.91 -0.48 (-0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$176.70 -0.21 (-0.12%)

As of 07:59 PM Eastern

Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play and YouTube; and devices, as well as in the provision of YouTube consumer subscription services. The Google Cloud segment offers infrastructure, cybersecurity, databases, analytics, AI, and other services; Google Workspace that include cloud-based communication and collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells healthcare-related and internet services. The company was incorporated in 1998 and is headquartered in Mountain View, California.

NVIDIA NASDAQ:NVDA

$153.30 -4.69 (-2.97%)

Closing price 04:00 PM Eastern

Extended Trading

$152.89 -0.41 (-0.27%)

As of 08:00 PM Eastern

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.13 +0.07 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$5.16 +0.04 (+0.68%)

As of 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Banco Santander NYSE:SAN

$8.26 -0.04 (-0.48%)

Closing price 03:59 PM Eastern

Extended Trading

$8.26 +0.01 (+0.06%)

As of 07:12 PM Eastern

Banco Santander, S.A. provides various financial services worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, mutual funds, and current and savings accounts; mortgages, consumer finance, loans, and various financing solutions; and project finance, debt capital markets, global transaction banking, and corporate finance services. The company also provides asset management and private banking services; and insurance products. In addition, it offers corporate and investment banking services; and digital payment solutions. Further, it offers online banking and financial services to retail, business, institutional, corporate, private banking and university customers and clients. The company was formerly known as Banco Santander Central Hispano SA and changed its name to Banco Santander, S.A. in February 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.

Schrodinger NASDAQ:SDGR

$20.61 +0.49 (+2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$20.91 +0.30 (+1.46%)

As of 07:38 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Sanofi NASDAQ:SNY

$49.05 +0.74 (+1.53%)

Closing price 04:00 PM Eastern

Extended Trading

$49.08 +0.04 (+0.07%)

As of 07:55 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi OTCMKTS:SNYNF

$96.54 +1.55 (+1.64%)

As of 03:28 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Earnings

Compare Dividends

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools